Dynaflow Resolve used in reserach showing potential new ways to treat pain
Chronic pain is a condition that affects approximately 20 percent of the adult population. Today, poor efficacy and…
Fluicell is transforming healthcare through innovative bioprinting and microfluidic research solutions, and tissue-based regenerative medicine, starting from the perspective of the individual cell.
Chronic pain is a condition that affects approximately 20 percent of the adult population. Today, poor efficacy and…
We are excited to announce the relaunch of our high-precision ion channel screening platform Dynaflow® Resolve. With Dynaflow…
Fluicell’s R&D team is demonstrating important progress in the Company’s type 1 diabetes therapeutics in vitro development and…